At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Akt Inhibitor MK2206 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor MK2206, Laboratory Biomarker Analysis, and 1 other intervention for Diffuse Large B Cell Lymphoma. Completed, enrolled 22 participants across 9 sites.
Detailed Summary
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Akt inhibitor MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B Cell Lymphoma
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionJun 2013
Study CompletionJun 2014
TodayJul 2026
First PostedNov 29, 2011
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.6 years ago
Interventions
Akt Inhibitor MK2206drug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies